MedTrace Logo

Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer

NCT02673398 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2023-06-18

Study results available
· View outcomes & findings →

Summary

This phase II trial studies the side effects of and how well neratinib works in treating older patients with stage IV HER2-positive breast cancer. Neratinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions

  • HER2 Positive Breast Carcinoma
  • Stage IV Breast Cancer AJCC v6 and v7

Interventions

OTHER

Comprehensive Geriatric Assessment

Ancillary studies

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Neratinib

Given PO

OTHER

Pharmacological Study

Correlative studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • City of Hope Medical Center

    lead OTHER

Principal Investigators

  • Mina Sedrak, MD · City of Hope Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-02
Primary Completion
2020-03-12
Completion
2022-09-22

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02673398 on ClinicalTrials.gov